Histotype
Pancreatic
| Parameter | Information |
|---|---|
| Strain | C57BL/6 |
| Implant Type | Cells |
| Implant Location | SC - Axilla (High) |
| Time to Staging | 6 days |
| Time to 750mm3 | 18.1 days |
| Td | 4.6 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Mouse
Ref #
9200
Murine Spotlight on Pan02
Learn more about this cell line in our scientific spotlights:
Pancreatic cancer is the ninth most commonly diagnosed cancer and ranks as one of the deadliest with the lowest 5-year survival rate of 5-8%.[1,2,3] This year alone, the American Cancer Society estimates that 56,770 people will be diagnosed with the disease of which more than 45,750 people may not survive. Pancreatic ductal adenocarcinoma (PDAC) being the most prevalent and aggressive form of exocrine pancreatic cancer accounts for ~90% of cases with mortality equaling incidence.[4,5]
Ductal Spotlight on Pan02
Learn more about this cell line in our scientific spotlights:
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer representing about 95% of all cases. In 2017, approximately 50,987 people will be diagnosed with PDAC in the United States, and approximately 40,936 patient deaths will occur, making PDAC one of the most lethal forms of cancer. Combination anti-metabolite and anti-mitotic taxane based chemotherapy is the standard of care in the US, but these treatment options historically only improve overall survival by weeks. There is a critical unmet medical need for novel therapeutic approaches to treat pancreatic cancer.